From Actos to act two

Why blood-brain penetration data convinced Ysios to lead Minoryx's series A

The improved properties of Minoryx Therapeutics S.L.'s backup PPAR gamma agonist versus lead molecule pioglitazone were enough to convince Ysios Capital to lead the rare disease company's €19.4 million ($22.1 million) series A round.

Minoryx is developing

Read the full 379 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE